Jefferies Believes ImmunoGen (NASDAQ: IMGN) Won’t Stop Here

By Carrie Williams

Jefferies analyst Eun Yang reiterated a Buy rating on ImmunoGen (NASDAQ: IMGN) on June 26 and set a price target of $6. The company’s shares closed yesterday at $6.54, close to its 52-week high of $7.

According to, Yang is a 4-star analyst with an average return of 3.7% and a 50.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $6.60, representing a 0.9% upside.

In a report issued on June 19, Leerink Swann also reiterated a Buy rating on the stock with a $11 price target.

The company has a one year high of $7 and a one year low of $1.51. Currently, ImmunoGen has an average volume of 2.51M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.